$SYIN - oops. There was a detail I missed from the January 10th PR. So they kind of estimated the time frame.
The trial is expected to commence in early 2026 and conclude later in the year. Data generated from the study is intended to inform future regulatory submissions and guide commercialization strategy in both healthcare and corporate markets.
The trial will be conducted under Synbio’s clinical and regulatory leadership, pursuant to its agreement with FacialDx Inc., the developer of the underlying facial analysis technology. Final execution remains subject to completion of the Statement of Work, cost schedules, and a Clinical Trial Research Agreement under the MSA framework.
Market Data 
Markets 
AI
